Vascular endothelial growth factor trap-eye
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Exudative Age-related Macular Degeneration
Conditions
Exudative Age-related Macular Degeneration
Trial Timeline
Dec 1, 2015 → Jan 20, 2019
NCT ID
NCT03169660About Vascular endothelial growth factor trap-eye
Vascular endothelial growth factor trap-eye is a approved stage product being developed by Bayer for Exudative Age-related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT03169660. Target conditions include Exudative Age-related Macular Degeneration.
What happened to similar drugs?
4 of 4 similar drugs in Exudative Age-related Macular Degeneration were approved
Approved (4) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03169660 | Approved | Completed |
Competing Products
5 competing products in Exudative Age-related Macular Degeneration
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ranibizumab | Novartis | Approved | 43 |
| ranibizumab | Novartis | Approved | 39 |
| LHA510 ophthalmic suspension + LHA510 vehicle + Ranibizumab ophthalmic solution | Novartis | Phase 2 | 35 |
| Aflibercept | Regeneron Pharmaceuticals | Approved | 43 |
| aflibercept | Bayer | Approved | 40 |